Nu-3 is under clinical development by Lakewood-Amedex and currently in Phase II for Diabetic Foot Ulcers. According to GlobalData, Phase II drugs for Diabetic Foot Ulcers does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Nu-3 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nu-3 overview
Nu-3 is under development for the treatment of complicated diabetic foot ulcer, Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus infection. The drug candidate is administered through intravenous, topical and pulmonary route. The drug candidate belongs to a class of anti-bacterial compounds bisphosphocins. The bisphosphocins act on the bacteria by disrupting the bacterial cell membrane.
The drug candidate was also under development for complicated systemic urinary tract infections, Lyme disease, chronic lung infection, ventilator-associated pneumonia, oral mucositis, pneumonia in cystic fibrosis patients and Mycobacterium tuberculosis infections.
Lakewood-Amedex overview
Lakewood-Amedex is a clinical-stage pharmaceutical company with focus on the development of antimicrobial and antifungal medicines to address unmet needs in the treatment of serious infectious diseases. The company develops anti-infective products such as anti-bacterial compounds, gene-silencing antivirals, locally delivered and orally available nanoRNA therapeutics. Its antimicrobial product pipeline includes Nu-3, small protonated nucleotide derivative molecules used for the treatment of complicated diabetic foot ulcers (cDFU); Nu-8, is intended to treat complicated urinary tract infections (cUTI) and Cystic Fibrosis. The company works in partnership with other biopharmaceutical companies, animal health companies, and academic and government institutions. Lakewood-Amedex is headquartered in Sarasota, Florida, the US.
For a complete picture of Nu-3’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
